Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 9

Results For "API"

2394 News Found

Zydus receives final approval from the USFDA for Olanzapine
News | March 13, 2023

Zydus receives final approval from the USFDA for Olanzapine

Olanzapine Orally Disintegrating Tablets are used to treat certain mental/mood conditions


Bachem raises $116 million through capital increase
News | March 11, 2023

Bachem raises $116 million through capital increase

Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies


Jubilant Pharmova receives VAI from USFDA for its API manufacturing facility
Drug Approval | March 09, 2023

Jubilant Pharmova receives VAI from USFDA for its API manufacturing facility

Based on this inspection and the USFDA VAI classification, this facility is in compliance with regard to current good manufacturing practices (cGMP)


Zydus receives final approval from the USFDA for Apixaban Tablets
Drug Approval | March 01, 2023

Zydus receives final approval from the USFDA for Apixaban Tablets

Apixaban Tablets, 2.5 mg and 5 mg had annual sales of USD 18,876 mn in the United States (IQVIA MAT Dec. 2022).


Piramal Pharma starts production at new API facility in Riverview, Michigan
News | February 20, 2023

Piramal Pharma starts production at new API facility in Riverview, Michigan

New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)


Janssen and Eli Lilly collaboration to address lack of pediatric therapies could rescue mirikizumab program, says GlobalData
News | February 06, 2023

Janssen and Eli Lilly collaboration to address lack of pediatric therapies could rescue mirikizumab program, says GlobalData

The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).


Merck named one of America’s Most JUST Companies by JUST Capital and CNBC
News | January 11, 2023

Merck named one of America’s Most JUST Companies by JUST Capital and CNBC

The JUST 100 is the only ranking that recognizes companies doing right by all their stakeholders as defined by the American public.


Ablaze and Yonghe Pharma initiate development and manufacturing agreement for targeted radiopharmaceutical therapies
News | December 28, 2022

Ablaze and Yonghe Pharma initiate development and manufacturing agreement for targeted radiopharmaceutical therapies

Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze


Lonza’s API manufacturing facility expansion in Nansha starts commercial operation
News | December 06, 2022

Lonza’s API manufacturing facility expansion in Nansha starts commercial operation

Expanded capacity in Nansha, China will support mid-scale manufacturing to ensure a smooth transition between early-phase and large-scale commercial production